{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:32:44Z","timestamp":1792683164371,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jbo.2024.100524","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T11:06:09Z","timestamp":1705057569000},"page":"100524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Epigenetic control of the vicious cycle"],"prefix":"10.1016","volume":"44","author":[{"given":"Madeline B.","family":"Searcy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2755-9851","authenticated-orcid":false,"given":"Rachelle W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2024.100524_b0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-020-01197-3","article-title":"Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy","volume":"19","author":"Lu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jbo.2024.100524_b0010","doi-asserted-by":"crossref","first-page":"e10126","DOI":"10.1002\/jbm4.10126","article-title":"Bone as a Preferential Site for Metastasis","volume":"3","author":"Sowder","year":"2019","journal-title":"JBMR plus"},{"key":"10.1016\/j.jbo.2024.100524_b0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrc.2016.44","article-title":"Bone metastasis: the importance of the neighbourhood","volume":"16","author":"Croucher","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbo.2024.100524_b0020","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-03-0118","article-title":"Very High Frequency of Hypermethylated Genes in Breast Cancer Metastasis to the Bone, Brain, and Lung","volume":"10","author":"Mehrotra","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2024.100524_b0025","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-021-01119-0","article-title":"A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer","volume":"13","author":"Ylitalo","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.jbo.2024.100524_b0030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1101\/gr.197194.115","article-title":"Enhancer methylation dynamics contribute to cancer plasticity and patient mortality","volume":"26","author":"Bell","year":"2016","journal-title":"Genome Res."},{"key":"10.1016\/j.jbo.2024.100524_b0035","doi-asserted-by":"crossref","first-page":"412","DOI":"10.4149\/neo_2017_312","article-title":"Expression of DNA methylation-related proteins in metastatic breast cancer","volume":"64","author":"Cha","year":"2017","journal-title":"Neoplasma"},{"key":"10.1016\/j.jbo.2024.100524_b0040","doi-asserted-by":"crossref","first-page":"5169","DOI":"10.18632\/oncotarget.23704","article-title":"Methyl donor S-adenosylmethionine (SAM) supplementation attenuates breast cancer growth, invasion, and metastasis in vivo; therapeutic and chemopreventive applications","volume":"9","author":"Mahoomd","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbo.2024.100524_b0045","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1111\/bph.13102","article-title":"Pharmacological methyl group donors block skeletal metastasis in vitro and in vivo","volume":"172","author":"Shukeir","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jbo.2024.100524_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315422","article-title":"The Binomial \u201cInflammation-Epigenetics\u201d in Breast Cancer Progression and Bone Metastasis: IL-1beta Actions Are Influenced by TET Inhibitor in MCF-7 Cell Line","volume":"23","author":"Bellavia","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbo.2024.100524_b0055","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/978-94-007-4525-4_13","article-title":"The role of DNA methylation and histone modifications in transcriptional regulation in humans","volume":"61","author":"Miller","year":"2013","journal-title":"Subcell. Biochem."},{"key":"10.1016\/j.jbo.2024.100524_b0060","doi-asserted-by":"crossref","unstructured":"Zhang, W. et al. The bone microenvironment invigorates metastatic seeds for further dissemination. Cell 184, 2471-2486 e2420, doi:10.1016\/j.cell.2021.03.011 (2021).","DOI":"10.1016\/j.cell.2021.03.011"},{"key":"10.1016\/j.jbo.2024.100524_b0065","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms4511","article-title":"Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle","volume":"5","author":"Lamoureux","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbo.2024.100524_b0070","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12951-023-01939-7","article-title":"Hypoxia-cleavable and specific targeted nanomedicine delivers epigenetic drugs for enhanced treatment of breast cancer and bone metastasis","volume":"21","author":"Li","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jbo.2024.100524_b0075","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s11914-021-00670-2","article-title":"Targeting Histone Modifications in Bone and Lung Metastatic Cancers","volume":"19","author":"Edwards","year":"2021","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.jbo.2024.100524_b0080","first-page":"2011","article-title":"Comparative role of acetylation along c-SRC\/ETS1 signaling pathway in bone metastatic and invasive mammary cell phenotypes","volume":"1767\u20131776","author":"Bendinelli","year":"1813","journal-title":"BBA"},{"key":"10.1016\/j.jbo.2024.100524_b0085","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1038\/s41388-021-01931-1","article-title":"HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer","volume":"40","author":"Clements","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.jbo.2024.100524_b0090","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/ncb3408","article-title":"Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow","volume":"18","author":"Johnson","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.jbo.2024.100524_b0095","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1200\/JCO.21.00944","article-title":"E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group","volume":"39","author":"Connolly","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2024.100524_b0100","doi-asserted-by":"crossref","unstructured":"O\u2019Shaughnessy, J. et al. Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC). J. Clin. Oncol. 38, 1014-1014, doi:10.1200\/JCO.2020.38.15_suppl.1014 (2020).","DOI":"10.1200\/JCO.2020.38.15_suppl.1014"},{"key":"10.1016\/j.jbo.2024.100524_b0105","doi-asserted-by":"crossref","first-page":"e13107","DOI":"10.1200\/JCO.2023.41.16_suppl.e13107","article-title":"A pilot study of the combination of entinostat with capecitabine in high-risk breast cancer after neoadjuvant therapy","volume":"41","author":"Humphrey","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2024.100524_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2021.100407","article-title":"HDAC inhibitors stimulate LIFR when it is repressed by hypoxia or PTHrP in breast cancer","volume":"31","author":"Edwards","year":"2021","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.jbo.2024.100524_b0115","doi-asserted-by":"crossref","first-page":"e10694","DOI":"10.1002\/jbm4.10694","article-title":"Select HDAC Inhibitors Enhance Osteolysis and Bone Metastasis Outgrowth but Can Be Mitigated With Bisphosphonate Therapy","volume":"7","author":"Clements","year":"2023","journal-title":"JBMR plus"},{"key":"10.1016\/j.jbo.2024.100524_b0120","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1152\/physrev.00004.2015","article-title":"Histone Deacetylases in Bone Development and Skeletal Disorders","volume":"95","author":"Bradley","year":"2015","journal-title":"Physiol. Rev."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137424000046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137424000046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:20:37Z","timestamp":1761942037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137424000046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":24,"alternative-id":["S2212137424000046"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2024.100524","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic control of the vicious cycle","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2024.100524","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100524"}}